{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:43:25Z","timestamp":1787319805083,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-GM129325"],"award-info":[{"award-number":["R01-GM129325"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-180300"],"award-info":[{"award-number":["PJT-180300"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bmcl.2026.130693","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:18:31Z","timestamp":1779466711000},"page":"130693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A simple solid-phase approach for the synthesis of DOTA-conjugated \u03b1-ketoamide-based fibroblast activation protein-targeted ligands"],"prefix":"10.1016","volume":"138","author":[{"given":"Shireen","family":"Jozi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Merkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finnley","family":"Cookson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Shyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130693_bb0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.bmcl.2026.130693_bb0010","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","article-title":"Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts","volume":"274","author":"Park","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130693_bb0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1367-5931(03)00084-X","article-title":"Prolyl peptidases: a serine protease subfamily with high potential for drug discovery","volume":"7","author":"Rosenblum","year":"2003","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.bmcl.2026.130693_bb0020","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2026.130693_bb0025","article-title":"Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2026.130693_bb0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.semnuclmed.2025.11.022","article-title":"Current status of FAP therapy in solid tumors","volume":"56","author":"Siegmund","year":"2026","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.bmcl.2026.130693_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030345","article-title":"Beyond small molecules: antibodies and peptides for fibroblast activation protein targeting radiopharmaceuticals","volume":"16","author":"Sun","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmcl.2026.130693_bb0040","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/acs.bioconjchem.3c00244","article-title":"A comparative analysis of fibroblast activation protein-targeted small molecule-drug, antibody-drug, and peptide-drug conjugates","volume":"34","author":"Zana","year":"2023","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmcl.2026.130693_bb0045","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","article-title":"Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides","volume":"50","author":"Millul","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bmcl.2026.130693_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113717","article-title":"Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with \u03b1-ketoamide warheads","volume":"224","author":"\u0160imkov\u00e1","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130693_bb0055","doi-asserted-by":"crossref","first-page":"21739","DOI":"10.1021\/acs.jmedchem.5c02102","article-title":"Structure\u2013property investigation of new \u201cketoFAPI\u201d inhibitors of fibroblast activation protein (FAP): discovery of highly potent, selective compounds with prolonged residence times and promising radiotheranostic potential","volume":"68","author":"Brzeminski","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130693_bb0060","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.bmcl.2012.03.107","article-title":"Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP\/prolyl oligopeptidase (PREP)-selectivity","volume":"22","author":"Ryabtsova","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130693_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70177","article-title":"Pioneering QSAR modeling study of FAP-targeting radiopharmaceuticals used in oncology","volume":"106","author":"Fatehi","year":"2025","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmcl.2026.130693_bb0070","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein\u2013targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmcl.2026.130693_bb0075","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmcl.2026.130693_bb0080","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure\u2013activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130693_bb0085","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/anie.201308984","article-title":"Systematic comparison of peptidic proteasome inhibitors highlights the \u03b1-ketoamide electrophile as an auspicious reversible lead motif","volume":"53","author":"Stein","year":"2014","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmcl.2026.130693_bb0090","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1021\/acs.jmedchem.0c01808","article-title":"The alpha keto amide moiety as a privileged motif in medicinal chemistry: current insights and emerging opportunities","volume":"64","author":"Robello","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130693_bb0095","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2967\/jnumed.124.267756","article-title":"Design of a fibroblast activation protein\u2013targeted radiopharmaceutical therapy with high tumor\u2013to\u2013healthy-tissue ratios","volume":"65","author":"Mukkamala","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmcl.2026.130693_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28031088","article-title":"Synthesis and preclinical evaluation of three novel 68Ga-labeled bispecific PSMA\/FAP-targeting tracers for prostate cancer imaging","volume":"28","author":"Verena","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130693_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.fob.2013.12.001","article-title":"Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs","volume":"4","author":"Keane","year":"2014","journal-title":"FEBS Open Bio"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:57:03Z","timestamp":1783137423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"alternative-id":["S0960894X26001605"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130693","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A simple solid-phase approach for the synthesis of DOTA-conjugated \u03b1-ketoamide-based fibroblast activation protein-targeted ligands","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130693"}}